{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"}]}],"title":"No events reported"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"14"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"groups":[{"description":"Received antimicrobial therapy alone.","id":"OG000","title":"Control Arm"},{"description":"Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.","id":"OG001","title":"Granulocyte Arm"}],"paramType":"NUMBER","populationDescription":"Subjects who received granulocyte transfusions. Six subjects in the control group received granulocyte transfusions in violation of the protocol.","reportingStatus":"POSTED","timeFrame":"Measured within 6 hours after end of transfusion","title":"Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)","type":"SECONDARY","unitOfMeasure":"participants"}